Denis Tvorogov

RSS feed of this list

  1. Methods and uses related to ADAMTS3

    Alitalo, K., Jeltsch, M., Jha, S. K. & Tvorogov, D., 30 Jul 2015, WIPO, Patent No. WO2015/110707, 30 Jul 2015, Priority date 24 Jan 2014, Priority No. 20145073 (FI)

    Research output: PatentScientific

  2. VEGFR-2-specific forms of VEGF-D and VEGF-C and uses thereof

    Alitalo, K. K., Jeltsch, M. M., Leppänen, V-M., Aho, K. K., Anisimov, A. & Tvorogov, D., 5 Jul 2012, WIPO, Patent No. WO2012/088563, 2 Jul 2012, Priority date 24 Nov 2010, Priority No. 61/458,517 (US)

    Research output: PatentScientific

  3. Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling

    Holopainen, T., Rasanen, M., Anisimov, A., Tuomainen, T., Zheng, W., Tvorogov, D., Hulmi, J. J., Andersson, L. C., Cenni, B., Tavi, P., Mervaala, E., Kivela, R. & Alitalo, K., 20 Oct 2015, In : Proceedings of the National Academy of Sciences of the United States of America. 112, 42, p. 13063-13068 6 p.

    Research output: Contribution to journalArticleScientificpeer-review

  4. Pulmonary Lymphangiectasia Resulting From Vascular Endothelial Growth Factor-C Overexpression During a Critical Period

    Yao, L-C., Testini, C., Tvorogov, D., Anisimov, A., Vargas, S. O., Baluk, P., Pytowski, B., Claesson-Welsh, L., Alitalo, K. & McDonald, D. M., 28 Feb 2014, In : Circulation Research. 114, 5, p. 806-822 17 p.

    Research output: Contribution to journalArticleScientificpeer-review

  5. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation

    Leppänen, V-M., Tvorogov, D., Kisko, K., Prota, A. E., Jeltsch, M., Anisimov, A., Markovic-Mueller, S., Stuttfeld, E., Goldie, K. N., Ballmer-Hofer, K. & Alitalo, K., 6 Aug 2013, In : Proceedings of the National Academy of Sciences of the United States of America. 110, 32, p. 12960-12965 6 p.

    Research output: Contribution to journalArticleScientificpeer-review

  6. The Basis for the Distinct Biological Activities of Vascular Endothelial Growth Factor Receptor-1 Ligands

    Anisimov, A., Leppanen, V-M., Tvorogov, D., Zarkada, G., Jeltsch, M., Holopainen, T., Kaijalainen, S. & Alitalo, K., 2 Jul 2013, In : Science signaling. 6, 282, p. ra52 10 p.

    Research output: Contribution to journalArticleScientificpeer-review

  7. Vascular Endothelial Growth Factor-Angiopoietin Chimera With Improved Properties for Therapeutic Angiogenesis

    Anisimov, A., Tvorogov, D., Alitalo, A., Leppänen, V-M., An, Y., Han, E. C., Orsenigo, F., Gaal, E. I., Holopainen, T., Koh, Y. J., Tammela, T., Korpisalo, P., Keskitalo, S., Jeltsch, M., Yla-Herttuala, S., Dejana, E., Koh, G. Y., Choi, C., Saharinen, P. & Alitalo, K., 2013, In : Circulation . 127, 4, p. 424-434 11 p.

    Research output: Contribution to journalArticleScientificpeer-review

  8. PV-1 is recognized by the PAL-E antibody and forms complexes with NRP-1

    Keuschnigg, J., Tvorogov, D., Elima, K., Salmi, M., Alitalo, K., Salminen, T. & Jalkanen, S., 5 Jul 2012, In : Blood. 120, 1, p. 232-235 4 p.

    Research output: Contribution to journalArticleScientificpeer-review

  9. Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth.

    Holopainen, T. T., López Alpuche, V., Zheng, W., Heljasvaara, R., Jones, D., He, Y., Tvorogov, D., D Amico Lago, G. V., Wiener, Z., Andersson, L. C., Pihlajaniemi, T., Min, W. & Alitalo, K., 15 Jul 2012, In : Cancer Research. 72, 14, p. 3512-3521 10 p.

    Research output: Contribution to journalArticleScientificpeer-review

Previous 1 2 Next